ICER Outlines Planned Review of Hemophilia A Treatments

January 24, 2020

The Institute for Clinical and Economic Review (ICER) released a draft scoping document outlining its planned review of two treatments for hemophilia A: BioMarin Pharmaceutical’s valoctocogene roxaparvovec and Genentech’s Hemlibra.

The document is open to public feedback until 5 p.m. EST Feb. 13.

To read the document, click here.

Click here to read the full press release.

Share This Story!